Contact hours available until 12/31/2020.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Nephrology Nursing Journal Editorial Board Statements of Disclosure:
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.

Paula Dutka, MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

Norma J. Gomez, MBA, MSN, CNNe, disclosed that she is a member of the ZS Pharma Advisory Council.

Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a member of the ANNA Board of Directors, serves on the Scientific Advisory Board for Kibow Biotech, Inc., and is employed by Fresenius Kidney Care as an acute hemodialysis RN.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Sally Russell, MN, CMSRN, CPP, ANNA Education Director.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses Association – Provider is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

This CNE article meets the Nephrology Nursing Certification Commission’s (NNCC’s) continuing nursing education requirements for certification and recertification.

Acknowledgements:
This study was supported by the Science and Technology Projects of Health Bureau of Shanghai (No 2009247).

Learning Outcome:
After completing this learning activity, the learner will be able to assess patients’ 24-hour blood pressure levels and use them as indicators of target organ damage to intervene and control cardiovascular risk factors as early as possible.

Learning Engagement Activity:
For more information on this topic, read the following article: Grezzana, G.B., Stein, A.T., & Pellanda, L.C. (2017). Twenty-four-hour ambulatory blood pressure monitoring for clinical evaluation of hypertensive patients in primary care: Which groups would most benefit? Blood Pressure Monitoring, 22(2), 72-78. doi:10.1097/MBP.0000000000000238

Yi Xuan MD

Appearances